ADDIN NE.Bib
[1] Ohmoto A,
Rokutan H,
Yachida S.
Pancreatic Neuroendocrine Neoplasms: Basic Biology,
Current Treatment Strategies and Prospects for the Future.
INT J MOL SCI 2017;18(1):143.
[2] Guilmette JM,
Nose V.
Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification,
Definition,
and Molecular Genetic Advances.
ADV ANAT PATHOL 2018.
[3] Birnbaum DJ,
Turrini O,
Vigano L,
et al.
Surgical Management of Advanced Pancreatic Neuroendocrine Tumors: Short-Term and Long-Term Results from an International Multi-institutional Study.
ANN SURG ONCOL 2015;22(3):1000-7.
[4] Partelli S,
Gaujoux S,
Boninsegna L,
et al.
Pattern and Clinical Predictors of Lymph Node Involvement in Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNETs).
JAMA SURG 2013;148(10):932.
[5] Choi SH,
Kim HJ,
Kim SY,
et al.
Computed Tomography Features Predictive of Lymph Node Involvement in Patients With a Nonfunctioning Pancreatic Neuroendocrine Tumor.
PANCREAS 2017;46(8):1056-63.
[6] Karaosmanoglu AD,
Onur MR,
Ozmen MN,
et al.
Magnetic Resonance Imaging of Liver Metastasis.
Seminars in Ultrasound,
CT and MRI 2016;37(6):533-48.
[7] De Robertis R,
D'Onofrio M,
Zamboni G,
et al.
Pancreatic Neuroendocrine Neoplasms: Clinical Value of Diffusion-Weighted Imaging.
NEUROENDOCRINOLOGY 2016;103(6):758-70.
[8] Al Ansari N.
Role of magnetic resonance imaging in the detection and characterization of solid pancreatic nodules: An update.
World Journal of Radiology 2015;7(11):361.
[9] Canellas R,
Lo G,
Bhowmik S,
et al.
Pancreatic neuroendocrine tumor: Correlations between MRI features,
tumor biology,
and clinical outcome after surgery.
J MAGN RESON IMAGING 2018;47(2):425-32.
[10] Nanno Y,
Matsumoto I,
Zen Y,
et al.
Pancreatic Duct Involvement in Well-Differentiated Neuroendocrine Tumors is an Independent Poor Prognostic Factor.
ANN SURG ONCOL 2017;24(4):1127-33.
[11] Barral M,
Sebbag-Sfez D,
Hoeffel C,
et al.
Characterization of focal pancreatic lesions using normalized apparent diffusion coefficient at 1.5-Tesla: preliminary experience.
Diagn Interv Imaging 2013;94(6):619-27.
[12] Lotfalizadeh E,
Ronot M,
Wagner M,
et al.
Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging.
EUR RADIOL 2017;27(4):1748-59.
[13] Klimstra DS,
Modlin IR,
Coppola D,
et al.
The pathologic classification of neuroendocrine tumors: a review of nomenclature,
grading,
and staging systems.
PANCREAS 2010;39(6):707-12.
[14] Löhr JM,
Panic N,
Vujasinovic M,
et al.
The ageing pancreas: a systematic review of the evidence and analysis of the consequences.
J INTERN MED 2018;283(5):446-60.
[15] Falconi M,
Eriksson B,
Kaltsas G,
et al.
ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.
NEUROENDOCRINOLOGY 2016;103(2):153-71.
[16] Yang M,
Tian BL,
Zhang Y,
et al.
Evaluation of the World Health Organization 2010 grading system in surgical outcome and prognosis of pancreatic neuroendocrine tumors.
PANCREAS 2014;43(7):1003-8.
[17] Hu Y,
Rao S,
Xu X,
et al.
Grade 2 pancreatic neuroendocrine tumors: overbroad scope of Ki-67 index according to MRI features.
ABDOM RADIOL 2018.
[18] Scarpa A,
Chang DK,
Nones K,
et al.
Whole-genome landscape of pancreatic neuroendocrine tumours.
NATURE 2017;543(7643):65-71.
[19] Genç CG,
Falconi M,
Partelli S,
et al.
Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
ANN SURG ONCOL 2018.
[20] De Robertis R,
Cingarlini S,
Tinazzi Martini P,
et al.
Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage.
WORLD J GASTROENTERO 2017;23(2):275.
[21] Sato T,
Ito K,
Tamada T,
et al.
Age-related changes in normal adult pancreas: MR imaging evaluation.
EUR J RADIOL 2012;81(9):2093-8.
[22] Okabe H,
Hashimoto D,
Chikamoto A,
et al.
Shape and Enhancement Characteristics of Pancreatic Neuroendocrine Tumor on Preoperative Contrast-enhanced Computed Tomography May be Prognostic Indicators.
ANN SURG ONCOL 2017;24(5):1399-405.
[23] Dick JE.
Stem cell concepts renew cancer research.
BLOOD 2008;112(13):4793-807.
[24] Jain RK,
Martin JD,
Stylianopoulos T.
The Role of Mechanical Forces in Tumor Growth and Therapy.
ANNU REV BIOMED ENG 2014;16(1):321-46.
[25] Yamamoto Y,
Okamura Y,
Uemura S,
et al.
Vascularity and Tumor Size are Significant Predictors for Recurrence after Resection of a Pancreatic Neuroendocrine Tumor.
ANN SURG ONCOL 2017;24(8):2363-70.
[26] Hashim YM,
Trinkaus KM,
Linehan DC,
et al.
Regional Lymphadenectomy Is Indicated in the Surgical Treatment of Pancreatic Neuroendocrine Tumors (PNETs).
ANN SURG 2014;259(2):197-203.
[27] Wong J,
Fulp WJ,
Strosberg JR,
et al.
Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience.
The American Journal of Surgery 2014;208(5):775-80.
[28] Parekh JR,
Wang SC,
Bergsland EK,
et al.
Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.
PANCREAS 2012;41(6):840-4.
[29] Gao S,
Pu N,
Liu L,
et al.
The latest exploration of staging and prognostic classification for pancreatic neuroendocrine tumors: a large population-based study.
J CANCER 2018;9(9):1698-706.